Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists map the hidden timeline of a deadly hantavirus

NCT ID NCT07703579

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This observational study follows people who have been exposed to Andes virus, a hantavirus that can cause severe respiratory illness. Researchers collect blood samples and monitor symptoms at key points from exposure through infection and recovery. The goal is to understand how the virus behaves in the body and how the immune system responds, without directing any medical care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal key patterns in how Andes virus infection progresses, helping design better treatments or vaccines for hantavirus diseases.
What could go wrong
This is a small observational study with only 15 participants, so findings may not apply broadly. It does not test any treatment, so it cannot directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

15 people

The number who actually took part.

Started

May 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consenting persons of any age who have a confirmed exposure to Andes virus and persons with confirmed Andes virus infection who are placed under confinement or quarantine or clinical care for active Andes virus infection. Participation in the NAVIS protocol does not restrict or prevent enrollment in other Hantavirus-related emergency responses or interventional clinical trials.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. No age restriction. 2. Persons diagnosed with or exposed to Andes Virus (ANDV). Exposure must comply with the national definition of ANDV exposure in each country, or satisfy at least one of the following criteria: 1. Direct physical exposure to a person with ANDV infection 2. Environmental and proximity exposure to a person with ANDV infection, i.e.: * Prolonged presence in an enclosed or poorly ventilated shared airspace. Note: Prolonged exposure is defined as cumulative exposure of 15 minutes or more within a 24-hour period in a confined space, or shared occupancy of an enclosed environment for more than 2 hours (ECDC). * Co-habitation in the same household, room, or cabin (e.g., maritime or shared residential settings). * Documented proximity during long-haul travel exceeding 4 hours. Note: Proximity is defined as sitting in an adjacent seat, defined as the same row or within two rows in front or behind. Long haul travel includes flight, bus, car or train. See Box 2 for justification of the 4 hour time threshold. 3. Occupational or caregiving exposure * Provision of direct healthcare or personal care to a person with ANDV infection without the consistent use of recommended Personal Protective Equipment (PPE). * Direct handling of potentially contaminated fomites, such as soiled linens, clothing, or bedding used by a confirmed case. * Direct handling of laboratory samples form a confirmed case with noncompliance with standard biosafety protocols. 3. Ability to comply with confinement sampling and follow up procedures. 4. Informed consent by participant, parent/legal guardian, or surrogate where allowed and applicable; assent or consent for children aged \<18 years or \<16 years as per local regulations. Exclusion Criteria: * 1\. Current imprisonment (quarantine does not count).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Andes hantavirus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Bichat

    Paris, 75018, France

  • Hôpital Pellegrin

    Bordeaux, 75018, France

  • La Pitié Salpêtrière

    Paris, 75018, France